Hey BE, I'm not trying to take a stab at you but you seem very...

First 235 Last

Share
Profile

Follow
simonjai

1,132 Posts.

179

11/02/18

11:02

Post #: 30974566
Share

Originally posted by Bullish Event ↑

Theres a few hypocrits here who were bagging me for wanting a pay cut until revenues for Nick at the AGM,and now what are some asking for,the same.
Some of these hypocrits went to the AGM and had their chance to make it official.
MOUs & LOIs just arent cutting it.

I didnt particularly see any problems with this latest announcement that wouldve justified the drop to 1.1c.
A loss of some premium content,whoop dee doo,we can get that back anywhere.
Some lucky people got to top up or average down very cheaply.
And some really dont have a clue what they're doing on the stockmarket selling lower than the SP they were waiting at for months when there is still more to come.
These are the goofballs responsible for the drop & the ones talking on HC like they know it all or are the research gurus.

Now we have to wait even longer.
When is Nick going to realise what the market wants,like i said before,still an amateur acting like a professional with regards to the stockmarket.
David shouldve had something positive to back it up with and they need to make Indonesia work more than ever now.

Same old story TV2.

Where is Alan Boyd?
What contributiin does he make?
When is Acshan gonna pull his finger out?

Expand

Hey BE, I'm not trying to take a stab at you but you seem very calm about this news and it's very surprising, but good to see.

At the AGM Nick seems to be very approachable, maybe you could try to reach out to him with your concerns/frustrations via LinkedIn? or try emailing him directly.

TV2 Price at posting: 1.3¢ Sentiment: Hold Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ZNC

Zenith's sale of Develin Creek delivers $975K cash, with shares up 13%

The iron ore comeback: Can it last?

HAS

Hastings progressing Yangibana to production with lower costs

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals